A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with onli ...

Inc. (NYSE American: PTN) has announced the completion of their Phase 2 clinical trial for an obesity treatment, marking a ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

Lexaria Bioscience (LEXX) provided progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4 underway in Australia. Lexaria has ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...